ESMO 2023 BioNTech Data

BNT221: Polyclonal T-Cell Responses in Drug Product are Detectable in Peripheral Blood Post-Infusion Phase 1 FIH study (NCT04625205): T cell response Borgers J. et al. Presented at ESMO 2023. Abstract #10170. Detection of specific CD8+ T cells by 105 tetramer DP Subset of responses in drug product are detected in periphery at 3-6 weeks. O Detected in DP ● Detected in DP and periphery O Detected in DP, not tested in periphery 100 100- о Tetramer 2 104 103- 0 0 105 104 2.45% 103 104 105 Post Infusion 103- 0.075% 103 104 10% Tetramer 1 DP: drug product; NAC: neoantigen cell dose received; NVD: never dosed. % pMHC+ of CD8+ 0.01 0.001 10. NAC01 800 0 0 φο o οφ оф 0 0 o NAC02 NAC03 NAC04 NAC05 oo 0000 oo o 01.000 NAC06 NVD01 NAC07 NAC08 NAC09 NVD02 NVD03 % IFNY and/or TNFa* of CD4+ 10- 0.1 NAC01 Офо 8 o do o 00 NAC02 NAC05 NAC06 NVD01 NAC07 NAC08 NAC09 NVD02 NVD03 ⚫ Of 12 patients tested, 2 had neoantigen-specific cells detected by flow cytometry in peripheral blood prior to infusion • Of the 5 patients with available sample 3-6 weeks post-infusion, all 5 had detectable CD8+ responses and 3 had detectable CD4+ responses BIONTECH

View entire presentation